Drugs / SII B.1.617.2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05029856 | Feb → Aug 2022 | COVID-19 | Novavax | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SII B.1.617.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05029856 ↗ |
| Modality | Vaccine | “Monovalent B.1.617.2 [Delta] variant strain vaccine” NCT05029856 ↗ |
| Route | Intramuscular | “Intramuscular (deltoid) injections of 5 μg SII B.1.617.2 and 50 μg Matrix-M1 Adjuvant” NCT05029856 ↗ |